The “Prevention Pipeline” from the Alzheimer´s Drug Discovery Foundation provides funding for studies, including clinical trials, that examine whether the use or choice of drugs affects dementia or cognitive decline in three main focus areas:
- Studies of Cognitive Decline and Risk Reduction
- Comparative Effectiveness Research
- Studies Leveraging the Consortium of Cohorts for Alzheimer’s Prevention Action (CAPA)
Funding is available to researchers worldwide, at both non-profit research institutions as well as for-profit organizations. Applicants may apply for up to 5 million USD (direct costs only) for multi-year funding support. There are three assessment rounds per year.
The next letter of intent is due September 29, 2023 and the full application is due on December 1, 2023.